There are 2789 resources available
606P - Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results
Presenter: Nuria Romero Laorden
Session: ePoster Display
607P - Impact of docetaxel on quality of life (QoL) in elderly and non-elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts)
Presenter: Silvia Rubio-Novella
Session: ePoster Display
608P - Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Presenter: Byung Ha Chung
Session: ePoster Display
609P - Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019
Presenter: Stephen Freedland
Session: ePoster Display
522P - Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
Presenter: Khobe Chandran
Session: ePoster Display
523P - AFP-maytansine conjugate: A novel targeted cancer immunotherapy
Presenter: Igor Sherman
Session: ePoster Display
524P - A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
Presenter: Melissa Johnson
Session: ePoster Display
525P - Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
Presenter: Meredith Mckean
Session: ePoster Display
526P - Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
Presenter: Pavani Chalasani
Session: ePoster Display
527P - Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)
Presenter: Debashis Sarker
Session: ePoster Display